Finch Therapeutics Group Inc
NASDAQ:FNCH
Intrinsic Value
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. [ Read More ]
The intrinsic value of one
FNCH
stock under the Base Case scenario is
0.53
USD.
Compared to the current market price of 2.31 USD,
Finch Therapeutics Group Inc
is
Overvalued by 77%.
FNCH's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
FNCH or that its price is influenced by factors unrelated to fundamentals.
Finch Therapeutics Group Inc's market capitalization is 3.7m USD.
FNCH stock price is 2.31 USD.
FNCH stock (0.53 USD) is 77% less than its price (2.31 USD).
FNCH. Open DCF Valuation
FNCH stock (0.53 USD) is 77% less than its price (2.31 USD). Open Relative Valuation
FNCH.
FNCH's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -66% to -54%, and is approaching profitability.
FNCH's long-term assets (55m USD) exceed its long-term liabilties (32m USD).
FNCH's Revenue has dropped by 88% over the past 12 months.
FNCH's ROE (Return on Equity) has significantly decreased in the last 3 years from -19% to -126%, and is approaching profitability.
FNCH has negative Operating Income for the last twelve months.
FNCH has negative Net Income for the last twelve months.
FNCH's ROE (Return on Equity) for the past 12 months is negative and is equal to -126%.
FNCH's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -54%.
FNCH has negative Free Cash Flow for the last twelve months.
FNCH's Revenue has been falling by 76% per year for the last 3 years.
FNCH has negative three-year average ROE (Return on Equity): -66%. The company is not efficient at transforming stockholders' equity into net income.
FNCH has negative three-year average ROIC (Return on Invested Capital): -76%. The company is not efficient at using invested capital to generate operating income.
FNCH's short-term assets (26m USD) exceed its short-term liabilties (4m USD).
FNCH's D/E (Debt to Equity) is very low and is equal to 0.
FNCH's Altman Z-Score is very low and is equal to -10.85.
FNCH doesn't generate enough operating income (-34m USD) to safely cover interest payments on its debt (202k USD).
Valuation Backtest
Finch Therapeutics Group Inc
Run backtest to discover the historical profit from buying and selling
FNCH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Finch Therapeutics Group Inc
Balance Sheet Decomposition
Finch Therapeutics Group Inc
| Current Assets | 25.8m |
| Cash & Short-Term Investments | 25.1m |
| Other Current Assets | 723k |
| Non-Current Assets | 29.5m |
| PP&E | 27.2m |
| Other Non-Current Assets | 2.3m |
| Current Liabilities | 4.1m |
| Accounts Payable | 141k |
| Accrued Liabilities | 3.9m |
| Non-Current Liabilities | 28.4m |
| Other Non-Current Liabilities | 28.4m |
Earnings Waterfall
Finch Therapeutics Group Inc
|
Revenue
|
107k
USD
|
|
Operating Expenses
|
-34.1m
USD
|
|
Operating Income
|
-34m
USD
|
|
Other Expenses
|
-40.8m
USD
|
|
Net Income
|
-74.8m
USD
|
Free Cash Flow Analysis
Finch Therapeutics Group Inc
What is Free Cash Flow?
FNCH Profitability Score
Profitability Due Diligence
Finch Therapeutics Group Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Finch Therapeutics Group Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
FNCH Solvency Score
Solvency Due Diligence
Finch Therapeutics Group Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Finch Therapeutics Group Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FNCH Price Targets Summary
Finch Therapeutics Group Inc
Ownership
FNCH Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
FNCH Price
Finch Therapeutics Group Inc
| Average Annual Return | 785 152.17% |
| Standard Deviation of Annual Returns | 1 110 508.13% |
| Max Drawdown | -100% |
| Market Capitalization | 3.7m USD |
| Shares Outstanding | 1 605 760 |
| Percentage of Shares Shorted | 1.01% |
Company Profile
Finch Therapeutics Group Inc
Country
Industry
Market Cap
Dividend Yield
Description
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Somerville, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2021-03-19. The firm leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. The company is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). The company is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.
Contact
IPO
Employees
Officers
The intrinsic value of one
FNCH
stock under the Base Case scenario is
0.53
USD.
Compared to the current market price of 2.31 USD,
Finch Therapeutics Group Inc
is
Overvalued by 77%.
You don't have any saved screeners yet
